Meeting
2023 ASCO Annual Meeting
EpCAM CAR T (IMC001) for the treatment of advanced GI cancers.
Authors
Tianhang Luo
Shanghai Changhai Hospital, Shanghai, Shanghai, China
Tianhang Luo , Weijia Fang , Zhengmao Lu , Chuchu Tong , Hangyu Zhang , Guoqiang Ai , Suqiong Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05028933
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4034)
DOI
10.1200/JCO.2023.41.16_suppl.4034
Abstract #
4034
Poster Bd #
355
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.
First Author: Weijia Fang
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
First Author: Dan Liu